Animals that were intraperitoneally (IP) injected with RvD2 (100 ng/mouse) three times a week showed a reduced degree of atherosclerosis, while in the presence of O-1918 (GPR18 antagonist), the positive effects of RvD2 were not observed [54]. Here, GPR18 is linked to atherosclerosis.